beta
/[Temporary Announcement] Weimen Pharmaceutical: Announcement of Resolutions of the Second Meeting of the Ninth Board of Supervisors
NEWS

[Temporary Announcement] Weimen Pharmaceutical: Announcement of Resolutions of the Second Meeting of the Ninth Board of Supervisors

NEEQ
2026/04/23

Announcement number: 2026-004

Securities code: 430369 Securities abbreviation: Weimen Pharmaceuticals Sponsoring broker: Shengang Securities

Guizhou Weimen Pharmaceutical Co., Ltd.

Announcement of Resolutions of the Second Meeting of the Ninth Supervisory Board

The Company and all members of the Supervisory Board guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability for the authenticity, accuracy and completeness of the contents.

1. Meeting convening and attendance

(1) Meeting status

  1. Meeting time: April 21, 2026

2.Meeting method: √On-site meeting □Electronic communication meeting

  1. Meeting location: Small conference room on the fourth floor of the e-commerce building of Guizhou Weimen Pharmaceutical Co., Ltd.

  2. Time and method of issuing notice of the Supervisory Board meeting: April 11, 2026 by communication 5. Meeting host: Mr. Yao Qiang, Chairman of the Supervisory Board

  3. Explanation on the legality and compliance of the convening situation:

The convening and resolution review procedures for this meeting were in compliance with relevant laws, regulations, departmental rules, normative documents and the Articles of Association.

(2) Meeting attendance

The meeting should be attended by 3 supervisors, and 3 supervisors should be present and authorized to attend the meeting.

2. Proposal review status

(1) Consideration and approval of the “Proposal on the Work Report of the Company’s 2025 Board of Supervisors”

  1. Contents of the motion:

The company's Board of Supervisors organized the preparation of the "Guizhou Weimen Pharmaceutical Co., Ltd. 2025 Board of Supervisors Work Report" based on the work situation in 2025. The chairman of the Supervisory Board reported on the work situation in 2025.

  1. Refusal to vote

Announcement number: 2026-004

There is no need to avoid voting on this motion.

  1. Voting results of the motion: 3 votes in favor; 0 votes against; 0 abstentions.

  2. Submit the voting status of the shareholders’ meeting:

This proposal still needs to be submitted to the shareholders' meeting for review.

(2) Consider and approve the “Proposal on the Company’s 2025 Annual Report and Summary”

  1. Contents of the motion:

For details, please refer to the "Guizhou Weimen Pharmaceutical Co., Ltd. 2025 Annual Report" (announcement number: 2026-005) and "Guizhou Weimen Pharmaceutical Co., Ltd. 2025 Annual Report Summary" (announcement number: 2026-006) disclosed by the company on the designated information disclosure platform of the National Equities Exchange and Quotations (www.neeq.com.cn) on April 23, 2026.

  1. Refusal to vote

There is no need to avoid voting on this motion.

  1. Voting results of the motion: 3 votes in favor; 0 votes against; 0 abstentions.

  2. Submit the voting status of the shareholders’ meeting:

This proposal still needs to be submitted to the shareholders' meeting for review.

(3) Deliberation and approval of the "About 2025 Funds of the Company's Controlling Shareholders, Actual Controllers and Other Related Parties"

Special explanation of occupancy situation》Proposal》

  1. Contents of the motion:

For details, please refer to the "Special Explanation on the Occupation of Funds by the Controlling Shareholders, Actual Controllers and Other Related Parties of Guizhou Weimen Pharmaceutical Co., Ltd." (Dehao Hezi [2026] No. 00001065) disclosed by the company on the designated information disclosure platform of the National Equities Exchange and Quotations (www.neeq.com.cn) on April 23, 2026.

  1. Refusal to vote

There is no need to avoid voting on this motion.

  1. Voting results of the motion: 3 votes in favor; 0 votes against; 0 abstentions.

  2. Submit the voting status of the shareholders’ meeting:

This proposal still needs to be submitted to the shareholders' meeting for review.

(4) Deliberation and approval of the "Special Report on the Deposit and Actual Use of the Company's Raised Funds in 2025"

motion"

Announcement number: 2026-004

  1. Contents of the motion:

For details, please refer to the "Special Report of Guizhou Weimen Pharmaceutical Co., Ltd. on the Storage and Use of Raised Funds" disclosed by the company on the designated information disclosure platform of the National Equities Exchange and Quotations (www.neeq.com.cn) on April 23, 2026 (Announcement No.: 2026-008)

  1. Refusal to vote

There is no need to avoid voting on this motion.

  1. Voting results of the motion: 3 votes in favor; 0 votes against; 0 abstentions.

  2. Submit the voting status of the shareholders’ meeting:

This proposal still needs to be submitted to the shareholders' meeting for review.

(5) Consider and approve the “Proposal on the Company’s 2025 Financial Final Account Report”

  1. Contents of the motion:

Based on the company's operating conditions and financial situation in 2025, the company prepared the "2025 Financial Final Account Report of Guizhou Weimen Pharmaceutical Co., Ltd.".

  1. Refusal to vote

There is no need to avoid voting on this motion.

  1. Voting results of the motion: 3 votes in favor; 0 votes against; 0 abstentions.

  2. Submit the voting status of the shareholders’ meeting:

This proposal still needs to be submitted to the shareholders' meeting for review.

(6) Consider and approve the “Proposal on the Company’s 2026 Financial Budget Report”

  1. Contents of the motion:

In accordance with the provisions of the Company Law and the Articles of Association of Guizhou Weimen Pharmaceutical Co., Ltd., the company prepared the "2026 Financial Budget Report of Guizhou Weimen Pharmaceutical Co., Ltd.".

  1. Refusal to vote

There is no need to avoid voting on this motion.

  1. Voting results of the motion: 3 votes in favor; 0 votes against; 0 abstentions.

  2. Submit the voting status of the shareholders’ meeting:

This proposal still needs to be submitted to the shareholders' meeting for review.

(7) Consideration and approval of the “Proposal on Confirming the Company’s Related Transactions in 2025”

  1. Contents of the motion:

Announcement number: 2026-004

For details, please refer to the "Guizhou Weimen Pharmaceutical Co., Ltd. Related Transaction Announcement" disclosed by the company on the designated information disclosure platform of the National Equities Exchange and Quotations (www.neeq.com.cn) on April 23, 2026 (announcement number: 2026-010).

  1. Refusal to vote

There is no need to avoid voting on this motion.

  1. Voting results of the motion: 3 votes in favor; 0 votes against; 0 abstentions.

  2. Submit the voting status of the shareholders’ meeting:

This proposal still needs to be submitted to the shareholders' meeting for review.

(8) Consider and approve the “Proposal on Estimating the Company’s Daily Related Transactions in 2026”

  1. Contents of the motion:

For details, please refer to the "Announcement of Guizhou Weimen Pharmaceutical Co., Ltd. on Estimated Daily Related Transactions in 2026" disclosed by the company on the designated information disclosure platform of the National Equities Exchange and Quotations (www.neeq.com.cn) on April 23, 2026 (announcement number: 2026-011).

  1. Refusal to vote

There is no need to avoid voting on this motion.

  1. Voting results of the motion: 3 votes in favor; 0 votes against; 0 abstentions.

  2. Submit the voting status of the shareholders’ meeting:

This proposal still needs to be submitted to the shareholders' meeting for review.

(9) Consideration and approval of the "About the Re-appointment of Beijing Dehao International Accounting Firm (Special General Partnership)" as the company

Proposal of the Audit Institution for 2026"

  1. Contents of the motion:

For details, please refer to the "Announcement on the Re-appointment of the Accounting Firm for 2026 by Guizhou Weimen Pharmaceutical Co., Ltd." (Announcement No.: 2026-012) disclosed by the company on the designated information disclosure platform of the National Equities Exchange and Quotations (www.neeq.com.cn) on April 23, 2026.

  1. Refusal to vote

There is no need to avoid voting on this motion.

  1. Voting results of the motion: 3 votes in favor; 0 votes against; 0 abstentions.

  2. Submit the voting status of the shareholders’ meeting:

This proposal still needs to be submitted to the shareholders' meeting for review.

Announcement number: 2026-004

(10) Consideration and approval of the “Proposal on the Company’s Profit Distribution in 2025”

  1. Contents of the motion:

Taking into account the company's future development needs and taking into account the company's current operating conditions and cash flow, the company will not distribute cash dividends this time and will not convert capital into equity.

  1. Refusal to vote

There is no need to avoid voting on this motion.

  1. Voting results of the motion: 3 votes in favor; 0 votes against; 0 abstentions.

  2. Submit the voting status of the shareholders’ meeting:

This proposal still needs to be submitted to the shareholders' meeting for review.

3. Documents for reference

"Resolution of the Second Meeting of the Ninth Supervisory Board of Guizhou Weimen Pharmaceutical Co., Ltd."

Board of Supervisors of Guizhou Weimen Pharmaceutical Co., Ltd.

April 23, 2026